上海医药：二羟丙茶碱注射液通过一致性评价

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for its Dihydrocodeine Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Dihydrocodeine Injection is indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The drug can also be used for alleviating symptoms caused by pulmonary edema due to heart disease [1]